Literature DB >> 17296740

Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.

Kerry L LaPlante1, Michael J Rybak, Brian Tsuji, Thomas P Lodise, Glenn W Kaatz.   

Abstract

The potential for resistance development in Streptococcus pneumoniae secondary to exposure to gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin at various levels was examined at high inoculum (10(8.5) to 10(9) log10 CFU/ml) over 96 h in an in vitro pharmacodynamic (PD) model using two fluoroquinolone-susceptible isolates. The pharmacokinetics of each drug was simulated to provide a range of free areas under the concentration-time curves (fAUC) that correlated with various fluoroquinolone doses. Potential first (parC and parE)- and second-step (gyrA and gyrB) mutations in isolates with raised MICs were identified by sequence analysis. PD models simulating fAUC/MICs of 51 and<or=60, 34 and 37, <or=82 and<or=86, and<or=24 for gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin, respectively, against each isolate were associated with first-step parC (S52G, S79Y, and N91D) and second-step gyrA (S81Y and S114G) mutations. For each fluoroquinolone a delay of first- and second-step mutations was observed with increasingly higher fAUC/MIC ratios and recovery of topoisomerase mutations in S. pneumoniae was related to the fAUC/MIC exposure. Clinical doses of gatifloxacin, gemifloxacin, and moxifloxacin exceeded the fAUC/MIC resistance breakpoint against wild-type S. pneumoniae, whereas those of levofloxacin (500 and 750 mg) were associated with first- and second-step mutations. The exposure breakpoints for levofloxacin were significantly different (P<0.001) from those of the newer fluoroquinolones gatifloxacin, gemifloxacin, and moxifloxacin. Additionally, moxifloxacin breakpoints were significantly lower (P<0.002) than those of gatifloxacin. The order of resistance development determined from fAUC/MIC breakpoints was levofloxacin>gatifloxacin>moxifloxacin=gemifloxacin, which may be related to structural differences within the class.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296740      PMCID: PMC1855487          DOI: 10.1128/AAC.00646-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.

Authors:  M E Jones; D F Sahm; N Martin; S Scheuring; P Heisig; C Thornsberry; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.

Authors:  E A Coyle; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 3.  The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective.

Authors:  C J Thomson
Journal:  J Antimicrob Chemother       Date:  1999-03       Impact factor: 5.790

4.  Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.

Authors:  P G Ambrose; D M Grasela; T H Grasela; J Passarell; H B Mayer; P F Pierce
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.

Authors:  T Lu; X Zhao; X Li; A Drlica-Wagner; J Y Wang; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

6.  Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae.

Authors:  Louis Saravolatz; Odette Manzor; Joan Pawlak; Bradley Belian
Journal:  Int J Antimicrob Agents       Date:  2005-07       Impact factor: 5.283

7.  Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.

Authors:  Genoveva Yague; Julia E Morris; Xiao-Su Pan; Katherine A Gould; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.

Authors:  H Taba; N Kusano
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 9.  In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.

Authors:  R N Jones; M A Pfaller
Journal:  Clin Infect Dis       Date:  2000-08       Impact factor: 9.079

10.  Primary targets of fluoroquinolones in Streptococcus pneumoniae.

Authors:  H Fukuda; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more
  8 in total

Review 1.  Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance.

Authors:  Chiara Adembri; Andrea Novelli
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

2.  Comparative pharmacokinetics and bioavailability of gemifloxacin administered as an intravenous 200 mg formulation or an oral 320 mg tablet.

Authors:  Mi Jo Kim; Hyeong-Seok Lim; Sang-Heon Cho; Kyun-Seop Bae
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

3.  Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use.

Authors:  Christopher R Frei; Matthew J Labreche; Russell T Attridge
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

4.  Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  Wolfgang Haas; Chris M Pillar; Christine K Hesje; Christine M Sanfilippo; Timothy W Morris
Journal:  J Antimicrob Chemother       Date:  2010-04-30       Impact factor: 5.790

5.  Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration.

Authors:  Gail Torkildsen; Joel W Proksch; Aron Shapiro; Stephanie K Lynch; Timothy L Comstock
Journal:  Clin Ophthalmol       Date:  2010-04-26

Review 6.  Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.

Authors:  Vanessa R Anderson; Caroline M Perry
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy.

Authors:  Ayman M Noreddin; Walid F Elkhatib; Kenji M Cunnion; George G Zhanel
Journal:  Drug Healthc Patient Saf       Date:  2011-10-07

Review 8.  Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.

Authors:  Cristian Jivcu; Mark Gotfried
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.